1. Home
  2. EDSA vs GDHG Comparison

EDSA vs GDHG Comparison

Compare EDSA & GDHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • GDHG
  • Stock Information
  • Founded
  • EDSA 2015
  • GDHG 2008
  • Country
  • EDSA Canada
  • GDHG China
  • Employees
  • EDSA N/A
  • GDHG N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • GDHG Services-Misc. Amusement & Recreation
  • Sector
  • EDSA Health Care
  • GDHG Consumer Discretionary
  • Exchange
  • EDSA Nasdaq
  • GDHG Nasdaq
  • Market Cap
  • EDSA 18.6M
  • GDHG 19.4M
  • IPO Year
  • EDSA N/A
  • GDHG 2023
  • Fundamental
  • Price
  • EDSA $1.73
  • GDHG $4.44
  • Analyst Decision
  • EDSA Strong Buy
  • GDHG
  • Analyst Count
  • EDSA 2
  • GDHG 0
  • Target Price
  • EDSA $13.00
  • GDHG N/A
  • AVG Volume (30 Days)
  • EDSA 908.6K
  • GDHG 47.6K
  • Earning Date
  • EDSA 12-12-2025
  • GDHG 07-11-2025
  • Dividend Yield
  • EDSA N/A
  • GDHG N/A
  • EPS Growth
  • EDSA N/A
  • GDHG N/A
  • EPS
  • EDSA N/A
  • GDHG N/A
  • Revenue
  • EDSA N/A
  • GDHG $16,666,899.00
  • Revenue This Year
  • EDSA N/A
  • GDHG N/A
  • Revenue Next Year
  • EDSA N/A
  • GDHG N/A
  • P/E Ratio
  • EDSA N/A
  • GDHG N/A
  • Revenue Growth
  • EDSA N/A
  • GDHG N/A
  • 52 Week Low
  • EDSA $1.55
  • GDHG $2.40
  • 52 Week High
  • EDSA $4.49
  • GDHG $1,968.41
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 35.70
  • GDHG 36.70
  • Support Level
  • EDSA $1.69
  • GDHG $3.96
  • Resistance Level
  • EDSA $1.83
  • GDHG $4.25
  • Average True Range (ATR)
  • EDSA 0.15
  • GDHG 0.25
  • MACD
  • EDSA -0.01
  • GDHG 0.08
  • Stochastic Oscillator
  • EDSA 17.00
  • GDHG 47.32

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About GDHG Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.

Share on Social Networks: